3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
57
Carboplatin
51
Bevacizumab
41
Taxes
28
liposomal doxorubicin
21
Gemcitabine
19
Immunoglobulin G
17
Disulfides
17
pembrolizumab
15
Topotecan
12
rucaparib
10
Cyclophosphamide
9
Cisplatin
9
Docetaxel
8
olaparib
7
Doxorubicin
7
pazopanib
6
mirvetuximab soravtansine
6
cediranib
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
sargramostim
4
niraparib
4
Surgical Procedures, Operative
4
Drug Therapy
4
Cytoreduction Surgical Procedures
4
Albumin-Bound Paclitaxel
4
veliparib
3
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Fallopian Tube Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts